Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?
- Autores
- Cunningham, Marla; Vinderola, Celso Gabriel; Charalampopoulos, Dimitris; Lebeer, Sarah; Sanders, Mary Ellen; Grimaldi, Roberta
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background: There is substantial demand for gut health products incorporating probiotics and prebiotics. They are being delivered as ingredients in an increasing range of different product formulations. While new delivery matrices are assessed for their potential impact on cell viability and prebiotic degradation, it is unknown whether they should be expected to independently alter the clinical effect of a given probiotic and prebiotic. Scope and approach: We provide an overview of preclinical and clinical data to examine the degree to which probiotic and prebiotic efficacy may be altered by processing and incorporation into various delivery matrices. We also consider the impact of inter-individual host factors on product efficacy. We further review regulatory positions across the globe on substantiation of prebiotic and probiotic efficacy in the final product format. Key findings and conclusions: In vitro data suggest that the delivery matrix may interact with prebiotic and probiotic functions via various physicochemical interactions with molecular and cellular structures and changes in cellular expression. However, direct evidence to suggest these changes have a significant in vivo impact is very limited. Indeed, meta-analyses suggest a robustness of effect across delivery matrices. Regulatory expectations vary among regions, but scope typically exists for adequate scientific justification to translate probiotic or prebiotic evidence across product formats. Early evidence suggests host factors such as diet, health and microbiome status are likely to play an important role in an individual´s response to a given probiotic and prebiotic.
Fil: Cunningham, Marla. No especifíca;
Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; Argentina
Fil: Charalampopoulos, Dimitris. University of Reading; Reino Unido
Fil: Lebeer, Sarah. Universiteit Antwerp; Bélgica
Fil: Sanders, Mary Ellen. International Scientific Association For Probiotics And Prebiotics; Estados Unidos
Fil: Grimaldi, Roberta. No especifíca; - Materia
-
DELIVERY MATRIX
HOST FACTORS
PREBIOTIC
PROBIOTIC
PRODUCT FORMULATION
REGULATORY - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/157469
Ver los metadatos del registro completo
id |
CONICETDig_d9b7d4e88f4e325b56efb39b618f1032 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/157469 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?Cunningham, MarlaVinderola, Celso GabrielCharalampopoulos, DimitrisLebeer, SarahSanders, Mary EllenGrimaldi, RobertaDELIVERY MATRIXHOST FACTORSPREBIOTICPROBIOTICPRODUCT FORMULATIONREGULATORYhttps://purl.org/becyt/ford/2.11https://purl.org/becyt/ford/2Background: There is substantial demand for gut health products incorporating probiotics and prebiotics. They are being delivered as ingredients in an increasing range of different product formulations. While new delivery matrices are assessed for their potential impact on cell viability and prebiotic degradation, it is unknown whether they should be expected to independently alter the clinical effect of a given probiotic and prebiotic. Scope and approach: We provide an overview of preclinical and clinical data to examine the degree to which probiotic and prebiotic efficacy may be altered by processing and incorporation into various delivery matrices. We also consider the impact of inter-individual host factors on product efficacy. We further review regulatory positions across the globe on substantiation of prebiotic and probiotic efficacy in the final product format. Key findings and conclusions: In vitro data suggest that the delivery matrix may interact with prebiotic and probiotic functions via various physicochemical interactions with molecular and cellular structures and changes in cellular expression. However, direct evidence to suggest these changes have a significant in vivo impact is very limited. Indeed, meta-analyses suggest a robustness of effect across delivery matrices. Regulatory expectations vary among regions, but scope typically exists for adequate scientific justification to translate probiotic or prebiotic evidence across product formats. Early evidence suggests host factors such as diet, health and microbiome status are likely to play an important role in an individual´s response to a given probiotic and prebiotic.Fil: Cunningham, Marla. No especifíca;Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; ArgentinaFil: Charalampopoulos, Dimitris. University of Reading; Reino UnidoFil: Lebeer, Sarah. Universiteit Antwerp; BélgicaFil: Sanders, Mary Ellen. International Scientific Association For Probiotics And Prebiotics; Estados UnidosFil: Grimaldi, Roberta. No especifíca;Elsevier Science London2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/157469Cunningham, Marla; Vinderola, Celso Gabriel; Charalampopoulos, Dimitris; Lebeer, Sarah; Sanders, Mary Ellen; et al.; Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?; Elsevier Science London; Trends In Food Science & Technology (regular Ed.); 112; 2021; 495-5060924-2244CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.tifs.2021.04.009info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0924224421002612?via%3Dihubinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:03:09Zoai:ri.conicet.gov.ar:11336/157469instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:03:09.724CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable? |
title |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable? |
spellingShingle |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable? Cunningham, Marla DELIVERY MATRIX HOST FACTORS PREBIOTIC PROBIOTIC PRODUCT FORMULATION REGULATORY |
title_short |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable? |
title_full |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable? |
title_fullStr |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable? |
title_full_unstemmed |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable? |
title_sort |
Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable? |
dc.creator.none.fl_str_mv |
Cunningham, Marla Vinderola, Celso Gabriel Charalampopoulos, Dimitris Lebeer, Sarah Sanders, Mary Ellen Grimaldi, Roberta |
author |
Cunningham, Marla |
author_facet |
Cunningham, Marla Vinderola, Celso Gabriel Charalampopoulos, Dimitris Lebeer, Sarah Sanders, Mary Ellen Grimaldi, Roberta |
author_role |
author |
author2 |
Vinderola, Celso Gabriel Charalampopoulos, Dimitris Lebeer, Sarah Sanders, Mary Ellen Grimaldi, Roberta |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
DELIVERY MATRIX HOST FACTORS PREBIOTIC PROBIOTIC PRODUCT FORMULATION REGULATORY |
topic |
DELIVERY MATRIX HOST FACTORS PREBIOTIC PROBIOTIC PRODUCT FORMULATION REGULATORY |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/2.11 https://purl.org/becyt/ford/2 |
dc.description.none.fl_txt_mv |
Background: There is substantial demand for gut health products incorporating probiotics and prebiotics. They are being delivered as ingredients in an increasing range of different product formulations. While new delivery matrices are assessed for their potential impact on cell viability and prebiotic degradation, it is unknown whether they should be expected to independently alter the clinical effect of a given probiotic and prebiotic. Scope and approach: We provide an overview of preclinical and clinical data to examine the degree to which probiotic and prebiotic efficacy may be altered by processing and incorporation into various delivery matrices. We also consider the impact of inter-individual host factors on product efficacy. We further review regulatory positions across the globe on substantiation of prebiotic and probiotic efficacy in the final product format. Key findings and conclusions: In vitro data suggest that the delivery matrix may interact with prebiotic and probiotic functions via various physicochemical interactions with molecular and cellular structures and changes in cellular expression. However, direct evidence to suggest these changes have a significant in vivo impact is very limited. Indeed, meta-analyses suggest a robustness of effect across delivery matrices. Regulatory expectations vary among regions, but scope typically exists for adequate scientific justification to translate probiotic or prebiotic evidence across product formats. Early evidence suggests host factors such as diet, health and microbiome status are likely to play an important role in an individual´s response to a given probiotic and prebiotic. Fil: Cunningham, Marla. No especifíca; Fil: Vinderola, Celso Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe. Instituto de Lactología Industrial. Universidad Nacional del Litoral. Facultad de Ingeniería Química. Instituto de Lactología Industrial; Argentina Fil: Charalampopoulos, Dimitris. University of Reading; Reino Unido Fil: Lebeer, Sarah. Universiteit Antwerp; Bélgica Fil: Sanders, Mary Ellen. International Scientific Association For Probiotics And Prebiotics; Estados Unidos Fil: Grimaldi, Roberta. No especifíca; |
description |
Background: There is substantial demand for gut health products incorporating probiotics and prebiotics. They are being delivered as ingredients in an increasing range of different product formulations. While new delivery matrices are assessed for their potential impact on cell viability and prebiotic degradation, it is unknown whether they should be expected to independently alter the clinical effect of a given probiotic and prebiotic. Scope and approach: We provide an overview of preclinical and clinical data to examine the degree to which probiotic and prebiotic efficacy may be altered by processing and incorporation into various delivery matrices. We also consider the impact of inter-individual host factors on product efficacy. We further review regulatory positions across the globe on substantiation of prebiotic and probiotic efficacy in the final product format. Key findings and conclusions: In vitro data suggest that the delivery matrix may interact with prebiotic and probiotic functions via various physicochemical interactions with molecular and cellular structures and changes in cellular expression. However, direct evidence to suggest these changes have a significant in vivo impact is very limited. Indeed, meta-analyses suggest a robustness of effect across delivery matrices. Regulatory expectations vary among regions, but scope typically exists for adequate scientific justification to translate probiotic or prebiotic evidence across product formats. Early evidence suggests host factors such as diet, health and microbiome status are likely to play an important role in an individual´s response to a given probiotic and prebiotic. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/157469 Cunningham, Marla; Vinderola, Celso Gabriel; Charalampopoulos, Dimitris; Lebeer, Sarah; Sanders, Mary Ellen; et al.; Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?; Elsevier Science London; Trends In Food Science & Technology (regular Ed.); 112; 2021; 495-506 0924-2244 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/157469 |
identifier_str_mv |
Cunningham, Marla; Vinderola, Celso Gabriel; Charalampopoulos, Dimitris; Lebeer, Sarah; Sanders, Mary Ellen; et al.; Applying probiotics and prebiotics in new delivery formats – is the clinical evidence transferable?; Elsevier Science London; Trends In Food Science & Technology (regular Ed.); 112; 2021; 495-506 0924-2244 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.tifs.2021.04.009 info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0924224421002612?via%3Dihub |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Science London |
publisher.none.fl_str_mv |
Elsevier Science London |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842980064312950784 |
score |
12.993085 |